Author: news_poster
Posted: Sun Feb 24, 2013 3:00 am
I’ve written in detail about the bold move by Reckitt-Benckiser that few people outside the company saw coming. In brief, the company has been cruising across the Atlantic for the past ten years, fueled by stellar growth of its flagship medication, Suboxone—even as the expiration of the patent on the medication loomed ahead (y’know– like an iceberg). […]<div>
<a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a> <a><img></img></a>
</div><img>
Source: Suboxone Talk Zone
A recovering psychiatrist talks about Suboxone, treatment for opiate dependence and chronic pain. Includes questions and answers with addicts and patients on Suboxone.